Category: Corporate NewsBy adminMay 17, 2020 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Disclosure to EGX on BOD minutesNextNext post:EGX disclosure regarding Rameda’s manufacturing of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture RemedsivirRelated PostsRameda Initiates First Acquisition of 2025July 7, 2025Record Dividend Distribution DisclosureJuly 7, 2025Rameda One-Pager 1Q25May 13, 2025Earnings Release One-Pager 4Q24March 10, 2025Earning Release One Pager 3Q24November 14, 2024Rameda Completes Largest Acquisition to DateSeptember 30, 2024
